title: Reiter syndrome triggered by adalimumab (Humira) and leflunomide (Arava) in a patient with ankylosing spondylarthropathy and Crohn disease.
authors.forename: A M
authors.initials: AM
authors.lastname: Thielen
authors.forename: C
authors.initials: C
authors.lastname: Barde
authors.forename: V
authors.initials: V
authors.lastname: Janer
authors.forename: L
authors.initials: L
authors.lastname: Borradori
authors.forename: J H
authors.initials: JH
authors.lastname: Saurat
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D016918:Arthritis, Reactive / Q000139:chemically induced* / Q000150:complications; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects*; D000077339:Leflunomide; D008297:Male; D025242:Spondylarthropathies / Q000188:drug therapy*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007555:Isoxazoles; D000068879:Adalimumab; D000077339:Leflunomide